Mereo BioPharma (MREO) Gross Margin (2023 - 2025)
Mereo BioPharma's (MREO) quarterly Gross Margin came in at 73.6% in Q2 2025, down 42.18% quarter-over-quarter from 127.3% in Q4 2023.
Powered by 
Analysis
Mereo BioPharma (MREO) Gross Margin (2023 - 2025) Analysis & Trends
Mereo BioPharma (MREO) has reported Gross Margin for 2 consecutive years, with 73.6% the latest figure, recorded in Q2 2025.
- On a quarterly basis, Gross Margin changed N/A year-over-year to 73.6% in Q2 2025; TTM through Jun 2026 was 73.6%, a 0.0% change from a year earlier, with the FY2025 full-year figure at 73.4%, changed N/A from the prior year.
- Gross Margin was 73.6% for Q2 2025 at Mereo BioPharma, down from 127.3% in the prior quarter.
- Over five years, Gross Margin peaked at 127.3% in Q4 2023 and troughed at 61.89% in Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 72.04% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 79.76% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 85.33% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 91.59% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 90.43% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 35.86% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 76.90% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 71.60% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 80.31% |
| 10 | Mereo BioPharma | 38.92 Mn | 38.92 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 73.60% |
| Dec 31, 2023 | 127.30% |
| Jun 30, 2023 | 61.89% |